Who are surufatinib + gemcitabine + nab-paclitaxel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PONATINIB HYDROCHLORIDE, Inlyta, Nilotinib 300 mg., imatinib (IM), Tislelizumab and nintedanib, Axitinib (AG-013736).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/surufatinib-gemcitabine-nab-paclitaxel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

surufatinib + gemcitabine + nab-paclitaxel — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

surufatinib + gemcitabine + nab-paclitaxel (surufatinib + gemcitabine + nab-paclitaxel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tyrosine kinase inhibitor. Area: Oncology.

phase 3 Tyrosine kinase inhibitor VEGFR, PDGFR, FGFR Oncology Small molecule Live · refreshed every 30 min

Target snapshot

surufatinib + gemcitabine + nab-paclitaxel (surufatinib + gemcitabine + nab-paclitaxel) — Tianjin Medical University Cancer Institute and Hospital. Surufatinib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), and fibroblast growth factor receptors (FGFR).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
surufatinib + gemcitabine + nab-paclitaxel TARGET	surufatinib + gemcitabine + nab-paclitaxel	Tianjin Medical University Cancer Institute and Hospital	phase 3	Tyrosine kinase inhibitor	VEGFR, PDGFR, FGFR
PONATINIB HYDROCHLORIDE	PONATINIB HYDROCHLORIDE		marketed		ABL, T315I mutant ABL, VEGFR, PDGFR, FGFR, EPH receptors, SRC family, KIT, RET, TIE2, FLT3	2012-01-01
Inlyta	Axitinib	Pfizer	marketed	Receptor tyrosine kinase inhibitor	Vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, VEGFR-3	2012-01-01
Nilotinib 300 mg.	Nilotinib 300 mg.	King Abdullah International Medical Research Center	marketed	BCR-ABL tyrosine kinase inhibitor	BCR-ABL
imatinib (IM)	imatinib (IM)	First Affiliated Hospital, Sun Yat-Sen University	marketed	Tyrosine kinase inhibitor	BCR-ABL, KIT, PDGFRA
Tislelizumab and nintedanib	Tislelizumab and nintedanib	The Affiliated Hospital of Qingdao University	marketed	PD-1 inhibitor + tyrosine kinase inhibitor combination	PD-1 (tislelizumab); VEGFR, FGFR, PDGFR (nintedanib)
Axitinib (AG-013736)	axitinib-ag-013736	Pfizer	marketed	tyrosine kinase inhibitor	vascular endothelial growth factor receptors (VEGFRs)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tyrosine kinase inhibitor class)

Jiangsu HengRui Medicine Co., Ltd. · 5 drugs in this class
Centre Leon Berard · 2 drugs in this class
AB Science · 2 drugs in this class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
Betta Pharmaceuticals Co., Ltd. · 1 drug in this class
Angion Biomedica Corp · 1 drug in this class
Beijing InnoCare Pharma Tech Co., Ltd. · 1 drug in this class
Chang-Ming Huang, Prof. · 1 drug in this class
Deciphera Pharmaceuticals, LLC · 1 drug in this class
AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). surufatinib + gemcitabine + nab-paclitaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/surufatinib-gemcitabine-nab-paclitaxel. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab